Needham analyst David Saxon raised the firm’s price target on SI-Bone (SIBN) to $24 from $20 and keeps a Buy rating on the shares. The company’s Q4 revenue was in line with its pre-announcement as procedure volume growth improved from the prior quarter and SI-Bone’s active surgeon base reached another record, the analyst tells investors in a research note. The management also guided to adjusted EBITDA profitability for 2025, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-Bone price target raised to $22 from $18 at Truist
- SI-Bone price target raised to $19 from $15 at Morgan Stanley
- SI-Bone’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- SI-Bone’s Strong Financial Performance and Promising Outlook Justifies Buy Rating and Raised Price Target
- SI-Bone: Strong Financial Performance and Strategic Positioning Justify Buy Rating